Open Access. Powered by Scholars. Published by Universities.®
Immunoprophylaxis and Therapy Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- 3D printing (1)
- AIDS (1)
- AIDS (Disease)—Prevention. Southern States (1)
- COVAX (1)
- COVID (1)
-
- COVID Open Pledge (1)
- CRISPR (1)
- CRISPR/Cas9 (1)
- Cas9 (1)
- Cas9/gRNA (1)
- Coronavirus (1)
- Federal aid to community health services (1)
- Gene editing (1)
- Gene therapy (1)
- Genetic engineering (1)
- HAART (1)
- HIV (1)
- HIV infections--Social aspects (1)
- HIV infections—Prevention (1)
- HIV-1 (1)
- Infectious diseases (1)
- Intellectual property (1)
- Nationalism (1)
- Pandemic (1)
- Patent pools (1)
- Patents (1)
- Pledge (1)
- Procurement (1)
- Recombinant DNA (1)
- Retrovirus (1)
Articles 1 - 4 of 4
Full-Text Articles in Immunoprophylaxis and Therapy
Development Of Vaccines And Antivirals Against Zika Virus, Aryamav Pattnaik
Development Of Vaccines And Antivirals Against Zika Virus, Aryamav Pattnaik
School of Veterinary and Biomedical Sciences: Dissertations, Theses, and Student Research
The re-emergence of Zika virus (ZIKV), an arbovirus, poses a major global human health concern because of its ability to cause congenital abnormalities and neurological diseases. While many candidate vaccines and antiviral drugs are in the developmental pipeline, none have been approved for use against ZIKV infection. This dissertation describes the characterization of one vaccine and two antiviral drug candidates against ZIKV infection. A bacterial ferritin-based nanoparticle vaccine, termed zDIII-F, is designed to display multiple copies of ZIKV E protein domain III on its surface. These stable nanoparticles are shown to induce robust antibody-mediated protection against lethal ZIKV infection in …
The Intellectual Property Of Covid-19, Ana Santos Rutschman
The Intellectual Property Of Covid-19, Ana Santos Rutschman
All Faculty Scholarship
The response to COVID-19 is indissolubly tied to intellectual property. In an increasingly globalized world in which infectious disease pathogens travel faster and wider than before, the development of vaccines, treatments and other forms of medical technology has become an integral part of public health preparedness and response frameworks. The development of these technologies, and to a certain extent the allocation and distribution of resulting outputs, is informed by intellectual property regimes. These regimes influence the commitment of R&D resources, shape scientific collaborations and, in some cases, may condition the widespread availability of emerging technologies. As seen throughout this chapter, …
Hiv Vaccines: Progress, Limitations And A Crispr/Cas9 Vaccine, Omar A. Garcia Martinez
Hiv Vaccines: Progress, Limitations And A Crispr/Cas9 Vaccine, Omar A. Garcia Martinez
Biology: Student Scholarship & Creative Works
ABSTRACT: The HIV-1 pandemic continues to thrive due to ineffective HIV-1 vaccines. Historically, the world’s most infectious diseases, such as polio and smallpox, have been eradicated or have come close to eradication due to the advent of effective vaccines. Highly active antiretroviral therapy is able to delay the onset of AIDS but can neither rid the body of HIV-1 proviral DNA nor prevent further transmission. A prophylactic vaccine that prevents the various mechanisms HIV-1 has to evade and attack our immune system is needed to end the HIV-1 pandemic. Recent advances in engineered nuclease systems, like the CRISPR/Cas9 system, have …
Hiv/Aids Care And Prevention Infrastructure In The U.S. Deep South, Susan S. Reif, Kristen Sullivan, Elena Wilson, Miriam Berger, Carolyn Mcallaster
Hiv/Aids Care And Prevention Infrastructure In The U.S. Deep South, Susan S. Reif, Kristen Sullivan, Elena Wilson, Miriam Berger, Carolyn Mcallaster
Faculty Scholarship
No abstract provided.